

PHOENIX CLINICAL TRIALS

Breast Cancer

B47 Chemo+/-Trastuz HER2low Adj Breast
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Hematological

Signature Series: PI3K Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - Bkm120 For Patients With PI3K-Activated Tumors

Signature Series: FCFR Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

Leukemia

CML Observational Trial - SIMPLICITY
Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

Azacitidine+BSC vs BSC AML Remission
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

SCN-35 CD30+ Non-Lymphoma Malignancies
A Phase II, Open-Label, Single-Arm Study of Brentuximab Vedotin in Patients with CD30-Positive Nonlymphomatous Malignancies

Nilotinib Discontinuation - CML Pts in MMR on imatinib
A Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib

Lung

LDK378 v SOC ALK+ NSCLC Post Chemo/Criz
A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Lymphomas

Brentuximab + R-CHOP, 1st Ln DLBCL
A Phase II Study of Brentuximab Vedotin in Combination with Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, And Prednisone [Rchop]) As Front-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma

Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Trabectedin +/- PLD Adv Ovarian 2/3 In
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Renal Cancer

PRINCIPAL Obs Study of Pazopanib in RCC
PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib

Solid Tumors

CD30 Screening in Solid Tumors and NHL
Screening Protocol to Detect Tumor Antigen Expression Required for Enrollment on Clinical Research Protocols of Antibody-Directed Therapy

**For more information or to refer a patient,
call 888-972-CURE.**

